The role of interleukin-13 in infectious diseases and allergy

BioEssays

Volumn 22, Issue 7, 2000, Pages 646-656

  Brombacher, Frank ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

IL13RA1 PROTEIN, HUMAN; IL13RA1 PROTEIN, MOUSE; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 4; INTERLEUKIN RECEPTOR;

ANIMAL; BIOLOGICAL MODEL; COMMUNICABLE DISEASE; HELMINTHIASIS; HUMAN; HYPERSENSITIVITY; IMMUNOLOGY; LEISHMANIA MAJOR; MOUSE; PHYSIOLOGY; REVIEW; TH2 CELL;

ANIMALS; COMMUNICABLE DISEASES; HELMINTHIASIS; HUMANS; HYPERSENSITIVITY; INTERLEUKIN-13; INTERLEUKIN-13 RECEPTOR ALPHA1 SUBUNIT; INTERLEUKIN-4; LEISHMANIA MAJOR; MICE; MODELS, BIOLOGICAL; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-13; TH2 CELLS;

EID: 0033949735     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-1878(200007)22:7<646::AID-BIES7>3.0.CO;2-9     Document Type: Review

References (88)

1. Thomson AW. The cytokine handbook. Academic Press. III. 1991. p 1-1017.
2. Zurawski G, de VJ. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 1994;15: 19-26.
3. de Saint Vis B, Fugier VI, Massacrier C, Gaillard C, Vanbervliet B, Ait YS, Banchereau J, Liu YJ, Lebecque S, Caux C. The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation. J Immunol 1998;160:1666-1676.
4. Hoshino T, Winkler-Pickett RT, Mason AT, Ortaldo JR, Young HA. IL-13 production by NK cells: IL-13-producing NK and T cells are present in vivo in the absence of IFN-γ. J Immunol 1999;162:51-59.
5. Kruse N, Tony HP, Sebald W. Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement. EMBO J 1992;11:3237-3244.
6. Aversa G, Punnonen J, Cocks BG, de Waal Malefyt R, Vega FJ, Zurawski SM, Zurawski G, de Vries JE. An interleukin 4 (IL-4) mutant protein inhibits both IL-4 or IL-13-induced human immunoglobulin G4 (IgG4) and IgE synthesis and B cell proliferation: support for a common component shared by IL-4 and IL-13 receptors. J Exp Med 1993;178: 2213-2218.
7. Obiri NI, Debinski W, Leonard WJ, Puri RK. Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J Biol Chem 1995;270:8797-8804.
8. Matthews DJ, Hibbert L, Friedrich K, Minty A, Callard RE. X-SCID B cell responses to interleukin-4 and interleukin-13 are mediated by a receptor complex that includes the interleukin-4 receptor alpha chain (p140) but not the gamma c chain. Eur J Immunol 1997;27:116-121.
9. Andersson A, Grunewald SM, Duschl A, Fischer A, DiSanto JP. Mouse macrophage development in the absence of the common gamma chain: defining receptor complexes responsible for IL-4 and IL-13 signaling. Eur J Immunol 1997;27:1762-1768.
10. Renard N, Duvert V, Banchereau J, Saeland S. Interleukin-13 inhibits the proliferation of normal and leukemic human B-cell precursors. Blood 1994;84:2253-2260.
11. Hilton DJ, Zhang JG, Metcalf D, Alexander WS, Nicola NA, Willson TA. Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor. Proc Natl Acad Sci USA 1996;93:497-501.
12. Aman MJ, Tayebi N, Obiri NI, Puri RK, Modi WS, Leonard WJ. cDNA cloning and characterization of the human interleukin 13 receptor alpha chain. J Biol Chem 1996;271:29265-29270.
13. Caput D, Laurent P, Kaghad M, Lelias JM, Lefort S, Vita N, Ferrara P. Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain J Biol Chem 1996;271:16921-16926.
14. Mohrs M, Lederman B, Koehler G, Dorfmueller A, Gessner A, Brombacher F. Differences between IL-4 and IL-4Rα deficient mice in chronic Leishmaniasis reveal a protective role for IL-13 receptor signalling. J Immunol 1999;162:7302.
15. Takeda K, Kamanaka M, Tanaka T, Kishimoto T, Akira S. Impaired IL-13-mediated functions of macrophages in STAT6-deficient mice. J Immunol 1996;157:3220-3222.
16. Donaldson DD, Whitters MJ, Fitz LJ, Neben TY, Finnerty H, Henderson SL, O'Hara RJ, Beier DR. Turner KJ, Wood CR, Collins M. The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1. J Immunol 1998;161: 2317-2324.
17. Feng N, Lugli SM, Schnyder B, Gauchat JF, Graber P, Schlagenhauf E, Schnarr B, Wiederkehr AM, Duschl A, Heim MH, Lutz RA, Moser R. The interleukin-4/interleukin-13 receptor of human synovial fibroblasts: over-expression of the nonsignaling interleukin-13 receptor alpha2. Lab Invest 1998;78:591-602.
18. Zhang JG, Hilton DJ, Willson TA, McFarlane C, Roberts BA, Moritz RL, Simpson RJ, Alexander WS, Metcalf D, Nicola NA. Identification, purification, and characterization of a soluble interleukin (IL)-13-binding protein. Evidence that it is distinct from the cloned II-13 receptor and II-4 receptor alpha-chains. J Biol Chem 1997;272: 9474-9480.
19. Jurg T, Wagner K, Neumann C, Heusser CH. Enhancement of human IL-4 activity by soluble IL-4 receptors in vitro. Eur J Immunol 1999;29: 864-871.
20. Kopf M, Le GG, Coyle AJ, Kosco VM, Brombacher F. Immune responses of IL-4, IL-5, IL-6 deficient mice. Immunol Rev 1995;148:45-69.
21. Magram J, Connaughton SE, Warrier RR, Carvajal DM, Wu CY, Ferrante J, Stewart C, Sarmiento U, Faherty DA, Gately MK. IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses. Immunity 1996;4:471-481.
22. Wu CY, Ferrante J, Gately MK, Magram J. Characterisation of IL-12 receptor β1 chain (IL-12Rβ1)-deficient mice. J Immunol 1997;159: 1658-1665.
23. Takeda K, Tsutsui H, Yoshimoto T, Adachi O, Yoshida N, Kishimoto T, Okamura H, Nakanishi K, Akira S. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 1998;8:383.
24. Kopf M, Le GG, Bachmann M, Lamers MC, Bluethmann H, Koehler G. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993;362:245-248.
25. Kopf M, Brombacher F. Kohler G, Kienzle G, Widmann KH, Lefrang K, Humborg C, Ledermann B, Solbach W. IL-4-deficient Balb/c mice resist infection with Leishmania major. J Exp Med 1996;184:1127-1136.
26. Brewer JM, Conacher M, Satoskar A, Bluethmann H, Alexander J. In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to freund's complete adjuvant, but continues to induce T helper 2 cytokine production. Eur J Immunol 1996;26:2062-2066.
27. Barner M, Mohrs M, Brombacher F, Kopf M. Differences between IL-4R alpha-deficient and IL-4-deficient mice reveal a role for IL-13 in the regulation of Th2 responses. Curr Biol 1998;8:669-672.
28. Takeda K, Tanaka T, Shi W, Matsumoto M, Minami M, Kashiwamura S, Nakanishi K, Yoshida N, Kishimoto T, Akira S. Essential role of STAT6 in IL-4 signalling. Nature 1996;380:627-630.
29. McKenzie GJ, Fallon P, Emson CL, Grencis R, McKenzie ANJ. Simultaneous disruption of Interleukin (IL)-4 and IL-13 defines individual roles in T helper cell type 2-mediated responses. J Exp Med 1999;189: 1565-1572.
30. + T cell, analyzed at the single-cell level. J Exp Med 1996;184: 473-483.
31. McKenzie GJ, Emson CL, Bell SE, Anderson S, Fallon P, Zurawski G, Murray R, Grencis R, McKenzie AN. Impaired development of Th2 cells in IL-13-deficient mice. Immunity 1998;9:423-432.
32. Emson CL, Bell SE, Jones A, Wisden W, McKenzie AN. Interleukin (IL)-4-independent induction of immunoglobulin (Ig)E and perturbation of T cell development in transgenic mice expressing IL-13. J Exp Med 1998;188:399-404.
33. Chiaramonte MG, Schopf LR, Neben TY, Cheever AW, Donaldson DD, Wynn TA. IL-13 is a key regulatory cytokine for Th2 cell-mediated pulmonary granuloma formation and IgE responses induced by Schistosoma mansoni eggs. J Immunol 1999;162:920-930.
34. Fowell DJ, Locksley RM. Leishmania major infection of inbred mice: unmasking genetic determinants of infectious diseases. BioEssays 1999;21:510-518.
35. Locksley RM, Heinzel FP, Holaday BJ, Mutha SS, Reiner SL, Sadick MD. Induction of Th1 and Th2 CD4+ subsets during murine Leishmania major infection. Res Immunol 1991;142:28-32.
36. Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med 1989;169:59-72.
37. Mattner F, Magram J, Ferrante J, Launois P, Di PK, Behin R, Gately MK, Louis JA, Alber G. Genetically resistan: mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur J Immunol 1996;26:1553-1559.
38. Noben-Trauth N, Kropf P, Muller I. Susceptibility to Leishmania major infection in interleukin-4-deficient mice. Science 1996;271: 987-990.
39. Noben-Trauth N, Paul WE, Sacks DL. IL-4 and IL-4 receptor deficient Balb/c mice reveal differences in susceptibility to Leishmania major parasite substrans. J Immunol 1999;162:6132-6140.
40. Matthews DJ, Emson CL, McKenzie GJ, Jolin HE, Blackwell JM, McKenzie ANJ. IL-13 is a susceptibility 'actor for Leishmania major infection. J Immunol 2000;164:1458-1462.
41. Mohrs M, Brombacher F, IL-4 receptor alpha deficient BALB/c mice show an unimpaired T helper2 polarization in response to Leishmania major infection. Infect Immun 2000; in press.
42. Kropf P, Schopf L, Chung C, Xu D, Liw FY, Sypek J, Muller I. Expression of Th2 cytokines and the stable Th2 marker ST2L in the absence of IL-4 during Leishmania major infection. Eur J Immunol 1999;29:3621-3628.
43. Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F de, Waal, Malefyt, R, Liu YJ. Reciprocal control of T helper cell and dendritic cell differentiation [see comments] Science 1999;283:1183-1186.
44. Satoskar A, Bluethmann H, Alexander J. Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovan infection. Infect Immun 1995;63:4894-4899.
45. Satoskar A, Brombacher F, Dai WJ, McInnes I, Liew FY, Alexander J, Walker W. SCID mice reconstituted with IL-4-deficient lymphocytes, but not immunocompetent lymphocytes, are resistant to cutaneous leishmaniasis. J Immunol 1997;159:5005-5013.
46. Johnston DA, Blaxter ML, Degrave WM, Foster J, Ivens AC, Melville SE Genomics and the biology of parasites. BioEssays 1999;21:131-147.
47. Finkelman FD, Shea-Donohue T, Goldhill J, Sullivan CA, Morris SC Madden KB, Gause WC, Urban JFJ. Cytokine regulation of host defense against parasitic gastrointestinal nematodes: lessons from studies with rodent animals. Ann Rev Immunol 1997;15:505.
48. Lawrence RA, Allen JE, Gregory WF, Kopf M, Maizels RM. Infection of IL-4-deficient mice with the parasitic nematode Brugia malayi demonstrates that host resistance is not dependent on a T helper 2-dominated immune response. J Immunol 1995;154:5995-6001.
49. Lawrence RA, Gray CA, Osborne J, Maizels RM. Nippostrongylus brasiliensis: cytokine responses and nematode expulsion in normal and IL-4 deficient mice. Exp Parasit 1997;84:65.
50. Noben-Trauth N, Shultz LD, Brombacher F, Urban JJ, Gu H, Paul WE. An interleukin 4 (IL-4)-independent pathway for CD4+ T cell IL-4 production is revealed in IL-4 receptor-deficient mice. Proc Natl Acad Sci USA 1997;94:10838-10843.
51. Shimoda K, van Deursen J, Sangster MY, Sarawar SR, Carson RT, Tripp RA, Chu C, Quelle FW, Nosaka T, Vignalli DAA, Doherty PC, Grosveld G, Paul WE, Ihle JN. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted STAT6 gene. Nature 1996;380: 630-633.
52. McKenzie GJ, Bancroft A, Grencis RK, McKenzie AN. A distinct role for interleukin-13 in Th2-cell-mediated immune responses. Curr Biol 1998;8: 339-342.
53. Urban JJ, Noben TN, Donaldson DD, Madden KB, Morris SC, Collins M, Finkelman FD. IL-13, IL-4Ralpna, and STAT6 are required for the expulsion of the gastrointestinal nematode parasite Nippostrongylus brasiliensis. Immunity 1998;8:255-264.
54. Bancroft AJ, McKenzie ANJ, Grencis RK. A critical role for IL-13 in resistance to intestinal nematode infection J Immunol 1998;160:3453-3461.
55. Brunet LR, Finkelman FD, Oneever AW, Kopf MA, Pearce EJ. IL-4 protects against TNF-alpha-mediated cachexia and death during acute schistosomiasis. Eur J Immunol 1997;159:777-785.
56. Kaplan MH, Whitfield JR, Boros DL Grusby MJ. Th2 cells are required for the Schistosoma mansoni egg-induced granulomatous response. J Immunol 1998;160:1850.
57. Cheever AW, Williams ME, Wynn TA, Finkelman FD, Seder RA, Cox TM, Hieny S, Caspar P, Sher A. Anti-IL-4 treatment of Schistosoma mansoni-infected mice inhibits development of T cells and non-B, non-T cells expressing Th2 cytokines while decreasing egg-induced hepatic fibrosis. J Immunol 1994;153:753-759.
58. Metwali A, Elliolt D, Blum AM, Li J, Sandor M, Lynch R, Noben TN, Weinstock JV. The granulomatous response in murine Schistosomiasis mansoni does not switch to Th1 in IL-4-deficient C57BL/6 mice J Immunol 1996;157:4546-4553.
59. Pearce EJ, Cheever A, Leonard S, Covalesky M, Fernandez BR Kohler G, Kopf M. Schistosoma mansoni in IL-4-deficient mice. Intern Immunol 1996;8:435-444.
60. Jankovic D, Kullberg MC Noben TN, Caspar P, Ward JM, Cheever AW, Paul WE, Sher A. Schistosome-Infected IL-4 Receptor Knockout (KO) Mice. in Contrast to IL-4 KO Mice, Fail to Develop Granulomatous Pathology While Maintaining the Same Lymphokine Expression Profile. J Immunol 1999;163:337-342.
61. Chiaramonte MG, Donaldson DD, Cheever AW, Wynn TA. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest 1999;104 777-785.
62. Walker C, Kaeg MK, Braun P, Blaser K. Activated T cells and eosinophilia in bronchoalveolar lavages from subjects with asthma correlated with disease severity. J Allergy Clin Immunol 1991;88:935-942.
63. Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, Corrigan C, Durham SR, Kay AB. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992;326:298-304.
64. Lukacs NW, Strieter RM, Chensue SW, Kunkel SL. Interleukin-4-dependent pulmonary eosinophil infiltration in a murine model of asthma. Am J Respir Cell Mol Biol 1994;10:526-532.
65. Brusselle GG, Kips JC, Tavernier JH, van dHJ, Cuvelier CA, Pauwels RA, Bluethmann H. Attenuation of allergic airway inflammation in IL-4 deficient mice. Clin Exp Allergy 1994;24:73-80.
66. Coyle AJ, Le GG, Bertrand C, Tsuyuki S, Heusser CH, Kopf M, Anderson GP. Interleukin-4 is required for the induction of lung Th2 mucosal immunity. Am J Respir Cell MoI Biol 1995;13:54-59.
67. Gavett SH, O'Hearn DJ, Karp CL, Patel EA. Schofield BH, Finkelman FD, Wills KM, Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice. Am J Physiol 1997;
68. Grunewald SM, Werthmann A, Schnarr B, Klein CE, Brocker EB, Mohrs M, Brombacher F, Sebald W, Duschl A. An antagonistic IL-4 mutant prevents type I allergy in the mouse: inhibition of the IL-4/IL-13 receptor system completely abrogates humoral immune response to allergen and development of allergic symptoms in vivo. J Immunol 1998;160: 4004-4009.
69. Campbell HD, Tucker WQ, Hort Y, Martinson ME, Mayo G, Clutterbuck EJ, Sanderson CJ, Young IG. Molecular cloning, nucleotide sequence, and expression of the gene encoding human eosinophil differentiation factor (interleukin 5). Proc Natl Acad Sci USA 1987;84:6629-6633.
70. Kopf M, Brombacher F Hodgkin PD, Ramsay AJ, Milbourne EA, Dai WJ, Ovington KS, Behm CA, Kohler G, Young IG, Matthaei KI. IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity 1996;4:15-24.
71. Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model [see comments] J Exp Med 1996; 183:195-201.
72. Hamelmann E, Oshiba A, Schwarze J, Bradley K, Loader J, Larsen GL, Gelfand EW. Allergen-specific IgE and IL-5 are essential for the development of airway hyperresponsiveness. Am J Respir Cell Mol Biol 1997;16:674-682.
73. Corry DB, Folkesson HG, Warnock ML, Erle DJ, Matthay MA, Wiener KJ, Locksley RM. Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity [see comments] [published erratum appears in J Exp Med 1997 May 5;185(9): 1715] J Exp Med 1996;183:109-117.
74. Corry DB, Folkesson HG, Warnock ML, Erle DJ, Matthay MA, Wiener KJ, Locksley RM. Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity [see comments] [published erratum appears in J Exp Med 1997 May 5;185(9): 1715] J Exp Med 1996;183:109-117.
75. Coyle AJ, Kohler G, Tsuyuki S, Brombacher F, Kopf M. Eosinophils are not required to induce airway hyperresponsiveness after nematode infection Eur J Immunol 1998;28:2640-2647.
76. Cohn L, Homer RJ, MacLeod H, Mohrs M, Brombache F, Bottomly K. Th2-induced airway mucus production is dependent on IL-4Ralpha, but not on eosinophils. J Immunol 1999;162:6178-6183.
77. Galli SJ. Complexity and redundancy in the pathogenesis of asthma: reassessing the roles of mast cells and T cells. J Exp Med 1997;186: 343-347.
78. Pawankar R, Okuda M, Yssel H, Okumura K, Ra C. Nasal mast cells in perennial allergic rhinitics exhibit increased expression of the Fc epsilonRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells [see comments]. J Clin Invest 1997;99:1492-1499.
79. Hamelmann E, Vella AT, Oshiba A, Kappler JW, Marrack P, Gelfand EW. Allergic airway sensitization induces T cell activation but not airway hyperresponsiveness in B cell-deficient mice. Proc Natl Acad Sci USA 1997;94:1350-1355.
80. Takeda K, Hamelmann E, Joetham A, Shultz LD, Larsen GL, Irvin CG, Gelfand EW. Development of eosinophilic airway inflammation and airway hyperresponsiveness in mast cell-deficient mice. J Exp Med 1997;186:449-454.
81. Hamelmann E, Tadeda K, Oshiba A, Gelfand EW. Role of IgE in the development of allergic airway inflammation and airway hyperresponsiveness-a murine model. Allergy 1999;54:297-305.
82. Minty A, Onalon P, Derocq JM, Dumont X, Guillemot JC, Kaghad M, Labit C, Leplatois P, Liauzun P, Miloux B, et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 1993;362:248-250.
83. Naseer T, Minshall EM, Leung DY, Laberge S, Ernst P, Martin RJ, Hamid Q. Expression of IL-12 and IL-13 mRNA in asthma and their modulation in response to steroid therapy. Am J Respir Crit Care Med 1997;155: 845-851.
84. Burd PR, Thompson WC, Max EE, Mills FC. Activated mast cells produce interleukin 13. J Exp Med 1995;181:1373-1380.
85. Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, Sheppard D, Mohrs M, Donaldson DD, Locksley RM, Corry DB. Requirement for IL-13 independently of IL-4 in experimental asthma [see comments]. Science 1998;282:2261-2263.
86. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD. Interleukin-13: central mediator of allergic asthma. Science 1998;282:2258-2261.
87. Kuperman D, Schofield B, Wills KM, Grusby MJ. Signal transducer and activator of transcription factor 6 (STAT6)-deficient mice are protected from antigen-induced airway hyperresponsiveness and mucus production. J Exp Med 1998;187:939-948.
88. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, Znang Y, Elias JA. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999;103: 779-788.